Cargando…

Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients

Background: Tissue plasminogen activator (tPA) has been long approved as an efficacious treatment in patients with acute ischemic stroke (AIS); however, due to some serious complications, particularly intracranial hemorrhage (ICH), many physicians are still reluctant to use it liberally. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadeghi-Hokmabadi, Elyar, Yazdchi, Mohammad, Farhoudi, Mehdi, Sadeghi, Homayoun, Taheraghdam, Aliakbar, Rikhtegar, Reza, Aliyar, Hannaneh, Mohammadi-Fallah, Sahar, Asadi, Rogayyeh, Mehdizadeh-Far, Elham, Ghaemian, Neda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121208/
https://www.ncbi.nlm.nih.gov/pubmed/30186557
_version_ 1783352415382142976
author Sadeghi-Hokmabadi, Elyar
Yazdchi, Mohammad
Farhoudi, Mehdi
Sadeghi, Homayoun
Taheraghdam, Aliakbar
Rikhtegar, Reza
Aliyar, Hannaneh
Mohammadi-Fallah, Sahar
Asadi, Rogayyeh
Mehdizadeh-Far, Elham
Ghaemian, Neda
author_facet Sadeghi-Hokmabadi, Elyar
Yazdchi, Mohammad
Farhoudi, Mehdi
Sadeghi, Homayoun
Taheraghdam, Aliakbar
Rikhtegar, Reza
Aliyar, Hannaneh
Mohammadi-Fallah, Sahar
Asadi, Rogayyeh
Mehdizadeh-Far, Elham
Ghaemian, Neda
author_sort Sadeghi-Hokmabadi, Elyar
collection PubMed
description Background: Tissue plasminogen activator (tPA) has been long approved as an efficacious treatment in patients with acute ischemic stroke (AIS); however, due to some serious complications, particularly intracranial hemorrhage (ICH), many physicians are still reluctant to use it liberally. This study sought to find potential prognostic factors in patients with AIS treated with tPA. Methods: A retrospective, hospital-bases observational study was conducted. Consecutively, a total of 132 patients with AIS treated with intravenous tPA, form June 2011 to July 2015 were enrolled. Inclusion and exclusion criteria were based on updated guidelines. Probable prognostic variables were examined separately in three distinct groups; the occurrence of ICH within 24 hours after treatment, poor 3-month outcome on the basis of modified Rankin Scale (mRS) and 3-month mortality. Results: Patients were 83 men (62.9%) and 49 women (37.1%) with a median age of 66 years [interquartile range (IQR)of 55-72]. Any type of hemorrhage, symptomatic hemorrhage [based on the European Cooperative Acute Stroke Study III (ECASS III) definition] within 24 hours posttreatment, poor 3-month outcome (mRS 3-6), and 3-month mortality were documented in 10.6%, 4.5%, 53.2%, and 23.6% of patients, respectively. Increased baseline blood glucose was a significant but dependent predictor of hemorrhage within the first 24 hours posttreatment. Dependent predictors of a 3-month poor outcome were high age, the National Institutes of Health Stroke Scale (NIHSS) at baseline, decreased admitting glomerular filtration rate (GFR), and the presence of atrial fibrillation (AF) rhythm, and ICH within 24 hours posttreatment. Only age [Odds ratio (OR) adjusted 1.05] and initial NIHSS (OR adjusted 1.23), however, were recognized as the independent variables in this regard. The only independent predictor of 3-month mortality was the initial NIHSS (OR adjusted 1.18). Conclusion: According to the findings of the present study, advanced age and high baseline NIHSS are two independent prognostic factors in patients with AIS treated with tPA.
format Online
Article
Text
id pubmed-6121208
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-61212082018-09-05 Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients Sadeghi-Hokmabadi, Elyar Yazdchi, Mohammad Farhoudi, Mehdi Sadeghi, Homayoun Taheraghdam, Aliakbar Rikhtegar, Reza Aliyar, Hannaneh Mohammadi-Fallah, Sahar Asadi, Rogayyeh Mehdizadeh-Far, Elham Ghaemian, Neda Iran J Neurol Original Article Background: Tissue plasminogen activator (tPA) has been long approved as an efficacious treatment in patients with acute ischemic stroke (AIS); however, due to some serious complications, particularly intracranial hemorrhage (ICH), many physicians are still reluctant to use it liberally. This study sought to find potential prognostic factors in patients with AIS treated with tPA. Methods: A retrospective, hospital-bases observational study was conducted. Consecutively, a total of 132 patients with AIS treated with intravenous tPA, form June 2011 to July 2015 were enrolled. Inclusion and exclusion criteria were based on updated guidelines. Probable prognostic variables were examined separately in three distinct groups; the occurrence of ICH within 24 hours after treatment, poor 3-month outcome on the basis of modified Rankin Scale (mRS) and 3-month mortality. Results: Patients were 83 men (62.9%) and 49 women (37.1%) with a median age of 66 years [interquartile range (IQR)of 55-72]. Any type of hemorrhage, symptomatic hemorrhage [based on the European Cooperative Acute Stroke Study III (ECASS III) definition] within 24 hours posttreatment, poor 3-month outcome (mRS 3-6), and 3-month mortality were documented in 10.6%, 4.5%, 53.2%, and 23.6% of patients, respectively. Increased baseline blood glucose was a significant but dependent predictor of hemorrhage within the first 24 hours posttreatment. Dependent predictors of a 3-month poor outcome were high age, the National Institutes of Health Stroke Scale (NIHSS) at baseline, decreased admitting glomerular filtration rate (GFR), and the presence of atrial fibrillation (AF) rhythm, and ICH within 24 hours posttreatment. Only age [Odds ratio (OR) adjusted 1.05] and initial NIHSS (OR adjusted 1.23), however, were recognized as the independent variables in this regard. The only independent predictor of 3-month mortality was the initial NIHSS (OR adjusted 1.18). Conclusion: According to the findings of the present study, advanced age and high baseline NIHSS are two independent prognostic factors in patients with AIS treated with tPA. Tehran University of Medical Sciences 2018-01-05 /pmc/articles/PMC6121208/ /pubmed/30186557 Text en Copyright © 2015 Iranian Neurological Association, and Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Sadeghi-Hokmabadi, Elyar
Yazdchi, Mohammad
Farhoudi, Mehdi
Sadeghi, Homayoun
Taheraghdam, Aliakbar
Rikhtegar, Reza
Aliyar, Hannaneh
Mohammadi-Fallah, Sahar
Asadi, Rogayyeh
Mehdizadeh-Far, Elham
Ghaemian, Neda
Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
title Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
title_full Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
title_fullStr Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
title_full_unstemmed Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
title_short Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients
title_sort prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: the first study among iranian patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121208/
https://www.ncbi.nlm.nih.gov/pubmed/30186557
work_keys_str_mv AT sadeghihokmabadielyar prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT yazdchimohammad prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT farhoudimehdi prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT sadeghihomayoun prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT taheraghdamaliakbar prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT rikhtegarreza prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT aliyarhannaneh prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT mohammadifallahsahar prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT asadirogayyeh prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT mehdizadehfarelham prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients
AT ghaemianneda prognosticfactorsinpatientswithacuteischemicstroketreatedwithintravenoustissueplasminogenactivatorthefirststudyamongiranianpatients